Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Enanta Pharmaceuticals (ENTA) Share Price
Headlines about Enanta Pharmaceuticals (NASDAQ:ENTA) have trended somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Enanta Pharmaceuticals earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.7250743813006 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the media headlines that may have effected Accern’s scoring:
- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Closed 17.0% Above Its 50 Day Average (highlightpress.com)
- Enanta Pharmaceuticals : to Present at Three Upcoming Investor Conferences (4-traders.com)
- Enanta Pharmaceuticals to Present at Three Upcoming Investor Conferences (finance.yahoo.com)
- Enanta Pharmaceuticals, Inc. (ENTA) Given Average Recommendation of “Buy” by Brokerages (americanbankingnews.com)
- Would You Buy Clovis Oncology, Inc. (NASDAQ:CLVS) On These Analyst Ratings? (techkenyot.com)
A number of analysts have recently weighed in on the stock. J P Morgan Chase & Co reiterated an “overweight” rating and set a $38.00 target price (up from $32.00) on shares of Enanta Pharmaceuticals in a report on Wednesday, August 9th. Robert W. Baird increased their target price on shares of Enanta Pharmaceuticals from $27.00 to $36.00 and gave the stock a “neutral” rating in a report on Tuesday, August 8th. Zacks Investment Research upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. JMP Securities upgraded shares of Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 target price for the company in a report on Tuesday, July 11th. Finally, BidaskClub upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 11th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Enanta Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $36.00.
Shares of Enanta Pharmaceuticals (ENTA) opened at 42.37 on Thursday. The stock’s 50 day moving average is $38.05 and its 200-day moving average is $32.98. Enanta Pharmaceuticals has a 12-month low of $21.52 and a 12-month high of $44.69. The stock’s market capitalization is $808.84 million.
Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.44) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.05. Enanta Pharmaceuticals had a negative net margin of 51.85% and a negative return on equity of 7.74%. The business had revenue of $7.51 million during the quarter, compared to analyst estimates of $8.08 million. During the same quarter last year, the firm posted ($0.06) earnings per share. The business’s revenue for the quarter was down 46.3% compared to the same quarter last year. On average, analysts expect that Enanta Pharmaceuticals will post $0.90 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Enanta Pharmaceuticals (ENTA) Share Price” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/31/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-enanta-pharmaceuticals-enta-share-price.html.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Stock Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.